Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation

Speiser, Burton L.; Spratling, Larry

doi:10.1016/0360-3016(93)90003-e

Cited by 122 publications

(56 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Later studies concluded that the use of a less aggressive technique would reduce the frequency of major complications, some of which would be as a result of progression of the neoplasm [3,14,17,18,21,26]. Other complications include pneumothorax, bronchospasm, bronchial stenosis and postirradiation pneumonitis [1,5,6,14,15,27]. The complications that occurred in the current study included one major complication (bronchial fistula) and three minor complications (bronchospasm, bronchial stenosis and pneumonitis).…”

Section: Discussionmentioning

confidence: 66%

Endobronchial brachytherapy in the treatment of malignant lung tumours

Escobar-Sacristan¹

2004

European Respiratory Journal

View full text Add to dashboard Cite

A prospective study was made to assess the short-term clinical and endoscopic response to high-dose-rate endobronchial brachytherapy (HDREB) in patients with malignant endobronchial tumours.From July 1995 to May 2000, 288 HDREB sessions were carried out on 81 patients. The mean patient age was 61.57 yrs (range 34-82); males were predominant (87.65%). Tumours were primary in 76 patients (93.82%) and metastatic in five patients (6.18%). The inclusion criteria were malignant endobronchial tumour and either palliative treatment for incurable disease or intent-to-cure treatment for residual malignancy on the bronchial resection surface after surgery or an inoperable tumour. The exclusion criteria were as follows: impediments to catheter placement, expected survival v2 months, Karnofsky index v60, or absence of informed consent. The clinical response of a symptom was categorised as complete (disappearance of the symptom), partial (less than complete) or absent. The endoscopic response was considered to be complete if lesions disappeared and biopsy findings remained negative 1 month after the last radiation session; partial if lesions improved to some extent, but the biopsy findings were positive; and absent if there was no change in relation to baseline. The technique consisted of delivering high-dose irradiation from an Ir 192 source to a target volume using one or two endobronchial catheters inserted under optical or video bronchoscopic guidance. Four sessions were scheduled at weekly intervals and 500 cGy was applied per session over a length of 1-9 cm, measured 0.5-1 cm from the centre of the source.In total, 85% of the symptoms analysed (haemoptysis, cough, dyspnoea, expectoration, and stridor) disappeared with HDREB, which was categorised as a complete response. The endoscopic response was complete in 56.79% of patients, partial or less than complete in 40.74% and absent in 2.46%. One major complication occurred (bronchial fistula 1.2%), but no lethal haemoptysis. Minor complications (pneumonitis, bronchospasm and bronchial stenosis) each occurred in one patient (1.2%).High-dose-rate endobronchial brachytherapy is a good palliative treatment for endoluminal lung neoplasms, effectively alleviating symptoms and endoscopic evidence in many cases with an acceptable rate of complications. High-dose-rate endobronchial brachytherapy can be carried out as an intent-to-cure procedure in highly selected cases.

show abstract

Section: Discussionmentioning

confidence: 66%

Endobronchial brachytherapy in the treatment of malignant lung tumours

Escobar-Sacristan¹

2004

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…The experience of HDR brachytherapy boost is extensive in the literature [21][22][23][24][25][26][27]. Patients selected for definitive external beam radiation and a brachytherapy boost were usually medically fit patients with centrally located stage IIIA or IIIB tumours, without weight loss in 6 months leading up to diagnosis.…”

Section: Hdr Brachytherapymentioning

confidence: 99%

“…Endobronchial brachytherapy is more widely practiced in many cancer centers [10,34]. Brachytherapyrelated complications have been graded and management has been proposed [25,35].…”

Section: Ldr Brachytherapymentioning

confidence: 99%

“…Treatment includes bed rest, codeine, fluid replacement, avoidance of anticoagulants, selective lung insulation and bronchial artery embolization. A brachytherapy related bronchitis grading system to enable comparison of complication between various dosefractionation regimens has been proposed by Speiser and Spratling [25] and management is summarized in Table 2.…”

Section: Ldr Brachytherapymentioning

confidence: 99%

See 1 more Smart Citation

Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach

Yu¹,

Lewis²,

Trejos³

et al. 2011

CRMR

View full text Add to dashboard Cite

New technological concepts have been evolving to manage the relative poor prognosis of lung cancer. Brachytherapy is becoming an option for both unresectable and early resectable lung cancer. Three-dimensional ultrasound (US) of lung tumours and image-guided minimally invasive robotics-assisted brachytherapy are feasible for dosimetry planning and management of lung tumours. The present article reviews the current knowledge of lung brachytherapy and discusses its potential in future management of lung cancer.

show abstract

“…Several long-term side effects have been reported following the procedure (e.g., broncho-vascular fistulae, radiation bronchitis and stricture); incident rates are variable according to different authors' experiences [7,8,13,[13][14][15].…”

Section: Introductionmentioning

confidence: 99%

High-Dose Rate Brachytherapy of Bronchial Cancer: Treatment Optimization Using Three Schemes of Therapy

et al. 2000

View full text Add to dashboard Cite

Results. Mean survival from diagnosis is 11.1 months and mean survival from last HDRBT is 9.7 months. The symptomatic response rate is 90% for dyspnea, 82% for cough, 94% for hemoptysis and 90% for obstructive pneumonia. Performance status was improved in 70% of patients. Follow-up is in the range of 5-36 months with 280/320 evaluable patients (87.5%) (40 patients were lost to follow-up). For the patients treated with three fractions of HDRBT plus EBRT, a smaller number of side effects occurred while relief from symptoms linked to bronchial obstruction and survival was similar for the three groups.Conclusions. A three-fraction brachytherapy results in fewer side effects, such as bronchial fibrosis with or without stenosis, while survival and symptomatic relief are similar in the three groups treated.

show abstract

Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation

Cited by 122 publications

References 15 publications

Endobronchial brachytherapy in the treatment of malignant lung tumours

Endobronchial brachytherapy in the treatment of malignant lung tumours

Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach

High-Dose Rate Brachytherapy of Bronchial Cancer: Treatment Optimization Using Three Schemes of Therapy

Contact Info

Product

Resources

About